The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Open Access
- 20 May 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (9) , 949-958
Abstract
Immune checkpoint inhibitors have revolutionized cancer treatment by targeting the cytotoxic T lymphocyte antigen-4 and programmed death-1/ligand-1. Although immune checkpoint inhibitors show promising therapeutic efficacy, they often cause immune-related adverse events. Immune-related adverse events differ from the side effects of conventional chemotherapy and require vigilant monitoring. These events predominantly affect organs, such as the colon, liver, lungs, pituitary gland, thyroid and skin, with rare cases affecting the heart, nervous system and other tissues. As immune-related adverse events result from immune activation, indicating the reinvigoration of exhausted immune cells that attack both tumors and normal tissues, it is theoretically possible that immune-related adverse events may signal a better response to immune checkpoint inhibitor therapy. Recent retrospective studies have explored the link between immune-related adverse event development and clinical efficacy; however, the predictive value of immune-related adverse events in the immune checkpoint inhibitor response remains unclear. Additionally, studies have focused on immune-related adverse events, timing of onset and immunosuppressive treatments. This review focuses on pivotal studies of the association between immune-related adverse events and outcomes in patients treated with immune checkpoint inhibitors.Keywords
This publication has 78 references indexed in Scilit:
- Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor TreatmentJAMA Dermatology, 2023
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung CancerJAMA Oncology, 2023
- Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced MelanomaJAMA Oncology, 2022
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung CancerJAMA Oncology, 2020
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2020
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or PlaceboJAMA Oncology, 2020
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung CancerJAMA Oncology, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung CancerJAMA Oncology, 2018
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerJAMA Oncology, 2018